Category: Study Design
Labels: results
Related questions: NA
Creation date and Author: Maria G., Mar 28th 2025
Last Update and Author: Astrid C., June 11th 2025
CURE51 will not grant you access to all the Results of the ROSALIND study.
The term "Results" is broad and includes a wide range of outputs — from raw omics data collected from all patients across approximately 100–200 participating centers, to potential drug targets identified by CURE51 through analysis of this data. These elements constitute the core value and intellectual property of CURE51 and, as such, cannot be shared.
However, CURE51 offers the partner centers access to the raw omics data from their patients. As a reminder, CURE51 is investing €5,000-€10,000 per patient sample to produce exceptionally deep and high-quality omics data. This valuable dataset is available for your unrestricted use in academic research.